Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

Vaccine. 2009 Apr 14;27(17):2394-401. doi: 10.1016/j.vaccine.2009.01.127. Epub 2009 Feb 6.


With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for approximately 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons > or =90yrs. Beyond the age of 4yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Child
  • Child, Preschool
  • Data Collection
  • Humans
  • Immunocompromised Host
  • Incidence
  • Infant
  • Infant, Newborn
  • Middle Aged
  • Netherlands / epidemiology
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / immunology
  • Pneumococcal Vaccines / immunology
  • Retrospective Studies


  • Pneumococcal Vaccines